List of works - Mark J Routbort

Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients

scientific article published on 26 June 2019

BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.

scientific article

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma

scientific article

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation

scientific article

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

scientific article

Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

scientific article

Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1

scientific article published on 01 April 2020

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients

scientific article published on 2 December 2016

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

scientific article

DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease

scientific article published on 07 May 2019

Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting

scientific article published on 27 October 2020

Distinct biological types of ocular adnexal sebaceous carcinoma: HPV-driven and virus-negative tumors arise through non-overlapping molecular-genetic alterations

scientific article published on 12 November 2018

Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma

scientific article published on 23 June 2019

Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels

scientific article published on 06 April 2018

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

scientific article published on 13 October 2020

Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases

scientific article

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.

scientific article published on 12 February 2016

Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring

scientific article published on 18 October 2013

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

scientific article published on 28 February 2020

P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival

scientific article published on 23 September 2018

Persistent mutations in remission can predict relapse in patients with acute myeloid leukemia

scholarly article by Chi Young Ok et al published February 2019 in Haematologica

Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments

scientific article published on 28 March 2019

Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome

scientific article published on 14 February 2018

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation

scientific article published on 29 August 2019

TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow

scientific article published on 30 September 2013

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

scientific article published on 8 May 2015

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories

scientific article published on 01 August 2018

List of works by Mark J Routbort

Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients

BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib

DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease

Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting

Distinct biological types of ocular adnexal sebaceous carcinoma: HPV-driven and virus-negative tumors arise through non-overlapping molecular-genetic alterations

Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma

Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.

Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival

Persistent mutations in remission can predict relapse in patients with acute myeloid leukemia

Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments

Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome

Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation

TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories